Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients

Cervical Cancer Clinical Trial

Official title:

Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients With Selected Intermediate-risk Factors: a Randomized Controlled Phase III Trials (ACCEPT Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05277688
• Other study ID #: 2021(237)
• Status: Recruiting
• Phase: Phase 3
• Start date: March 15, 2022
• Est. completion date: December 30, 2027

Study information

• Verified date: March 2022
• Source: Ruijin Hospital
• Contact: Wei-Xiang Qi, Dr.
• Phone: +862164370045
• Email: qiweixiang1113[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.

Description:

Adjuvant therapy for patients with cervical cancer (CC) with intermediate-risk factors remains controversial. According to result of GOG 92 trail, adjuvant radiotherapy significantly improved recurrence-free survival in early stage cervical cancer with intermediate risks (Sedlis criteria). However, significant heterogeneity exists in Sedlis criteria, high risk of relapse and death occurred in patients with (1) lympho-vascular space invasion(LVSI+) and deep 1/3 stromal invasion;(2) LVSI(+) and middle 1/3 stromal invasion, and tumor size≥4cm when compared with other factors. In addition, multiple studies have confirmed that (3)non-squamous histology is an independent prognostic factor in early stage cervical cancer, who might be benefited from adjuvant concurrent chemoradiotherapy. As a result, The objective of the trial is to evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery. The primary endpoint of the study is the recurrence-free survival from the day of randomization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 340
• Est. completion date: December 30, 2027
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• • 18 Years to 80 Years

• Histologically proven cervical cancer, FIGO stage Ia2-IIb,and no previous chemotherapy and radiotherapy

• Accepted radical hysterectomy 3-4 weeks before

• Karnofsky score >70

• Postoperative pathology with one of the three risk factors criterials: (1) lympho-vascular space invasion(LVSI+) and deep 1/3 stromal invasion; (2 ) LVSI(+) and middle 1/3 stromal invasion, and tumor size=4cm (3)Non-squamous cell carcinoma;

• Examination results showed no radiation or chemotherapy contraindication

• Willing to accept treatment

• Ability to comply with trial requirements

Exclusion Criteria:

• • Postoperative residual

• Postoperative recurrence or metastasis

• Pelvic lymph node metastasis

• parametrial invasion

• positive surgical margin

• Without lymph node dissection

• Postoperative pathology showed aortic lymph node metastasis

• Examination results showed radiotherapy contraindications

• No indications for radiotherapy

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• adjuvant concurrent chemoradiotherapy
concurrent chemotherapy: cisplatin(DDP) weekly, 40mg/m2, begin with radiation Drug: cisplatin(DDP) weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.

Radiation:
• radiotherapy
Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.

Locations

Country	Name	City	State
China	Ruijin Hospital, Shanghai jiaotong univestigy school of medicine	Shanghai	Shanghai
China	Ruijin Hospital, Shanghai jiaotong univestigy school of medicine	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	5-year recurrence-free survival	From date of surgery until the date of first documented local-regional progression or distant metastasis (determined by CT or MRI scan and/or biopsy) or death (from any cause) assessed up to five years.	5 years
Secondary	5-year overall survival	Determine the 5-year overall survival rate in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to death of all cause at time of 5 years after operation.	5 years
Secondary	Acute toxicity	Evaluate the treatment induced toxicity according to CTCAE 4.0 during the time of chemoradiotherapy or radiotherapy alone which starts from the first day of Endostar and lasts three months.	3 months
Secondary	Quality of Life (QoL)	Collect QoL data on early-stage cervical cancer patients with high risk factors. The data is measured by EORTC QLQ-C30 (Version 3.0) according to investigator collection at the starting and ending time of the adjuvant treatment. EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. The core and disease-specific for cervix modules are selected to estimate treatment related influence on patients' life. The final score of the questionnaire is collected and analyzed according to detailed scoring procedures from manuals.	2 years